New studies

We are fully engaged in the market validation of viQtor.

This month we will start monitoring COPD patients from General Practition Practice Meuwissen, van Ballegooijen and Vosseberg in Wageningen.
In this study we investigate whether and how we can demonstrate deterioration of the condition of these patients using the data we collect with viQtor. We also want to gain insight into how viQtor can be best used in a general practice.

Leiden University Medical Center (LUMC)

And we will start a study together with Leiden University Medical Center (LUMC). High-risk patients spend a short period of time in a Post Anaesthesia Care Unit (PACU) after surgery. The number of beds in a PACU unit is scarce and this care is relatively expensive.
Together with LUMC, we will investigate whether we can also monitor these patients safely with viQtor. This could eventually mean that patients can be moved to a regular nursing unit sooner.

This way, we aim to contribute substantially to the availability of scarce care resources. We look forward to gaining the new insights from these studies.

Radboud UMC (Nijmegen) en ErasmusMC (Rotterdam)

In addition, we are working with Radboud UMC (Nijmegen) and ErasmusMC (Rotterdam) on a plan that should lead to further clinical substantiation and new examples for the use of viQtor.
In these cases viQtor will be used for monitoring in regular hospital wards and also for monitoring patients after discharge in the home setting.

It is expected that viQtor can add substantial value in various places and for various patients and relieve and improve work for the healthcare providers involved.
Positive results from studies and experiences from use cases in which viQtor is used will help to convince other healthcare providers and insurers of the effective use of continuous monitoring with viQtor.